Market Access Time to ask companies why they don’t submit to NICE? Companies can choose whether or not to submit to NICE to have their products appraised.
Views & Analysis VPAS: Achievements so far on affordability In the second part of this series taking stock of
Views & Analysis VPAS: Achievement so far on objectives for patients The UK has a voluntary agreement that was struck by the government and NHS England (now referred to as NHSE&I) with the Association of the British Pharmaceutical Industry (ABPI) in 2018
Oncology Liver cancer diagnostic gets FDA breakthrough status, with P... Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
